검색
Ionis Pharmaceuticals Inc
IONS관심 목록에 추가
75.710USD
-0.310-0.41%
종가 05/08, 16:00（ET）시세는 15분 지연됩니다
12.51B시가총액
손실P/E TTM
자세한 내용은 Ionis Pharmaceuticals Inc 회사
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals Inc 정보
종목 코드 IONS
회사 이름Ionis Pharmaceuticals Inc
상장일May 17, 1991
CEOMonia (Brett P)
직원 수1069
유형Ordinary Share
회계 연도 종료May 17
주소2855 Gazelle Court
도시CARLSBAD
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호92010
전화17609319200
웹사이트https://www.ionis.com/
종목 코드 IONS
상장일May 17, 1991
CEOMonia (Brett P)
Ionis Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.66K
-5.08%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
67.50K
+1.34%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
62.21K
-16.31%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
59.86K
-9.71%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
32.68K
+0.61%
Mr. Kyle Jenne
Mr. Kyle Jenne
Executive Vice President, Chief Global Product Strategy Officer
Executive Vice President, Chief Global Product Strategy Officer
23.71K
+30.89%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.66K
-5.08%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
67.50K
+1.34%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
62.21K
-16.31%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
59.86K
-9.71%
수익 분석
통화: USD마지막 업데이트: Mar 4, 2025
통화: USD마지막 업데이트: Mar 4, 2025
FY2020
FY2019
사업별USD
이름
수익
비율
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
주식 보유 통계
마지막 업데이트: 16 hours ago
마지막 업데이트: 16 hours ago
주주
주주 유형
주주
주주
비율
Fidelity Management & Research Company LLC
14.57%
Capital World Investors
10.87%
T. Rowe Price Investment Management, Inc.
5.51%
BlackRock Institutional Trust Company, N.A.
5.22%
Vanguard Portfolio Management, LLC
4.73%
기타
59.10%
주주
주주
비율
Fidelity Management & Research Company LLC
14.57%
Capital World Investors
10.87%
T. Rowe Price Investment Management, Inc.
5.51%
BlackRock Institutional Trust Company, N.A.
5.22%
Vanguard Portfolio Management, LLC
4.73%
기타
59.10%
주주 유형
주주
비율
Investment Advisor
82.89%
Investment Advisor/Hedge Fund
19.99%
Hedge Fund
12.11%
Research Firm
1.99%
Pension Fund
1.17%
Bank and Trust
0.87%
Individual Investor
0.72%
Sovereign Wealth Fund
0.19%
Insurance Company
0.16%
기관 주식 보유
마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
942
197.51M
119.51%
+12.09M
2025Q4
884
176.89M
109.21%
-8.44M
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Fidelity Management & Research Company LLC
24.07M
14.57%
+383.06K
+1.62%
Dec 31, 2025
Capital World Investors
17.96M
10.87%
+5.24M
+41.17%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
9.11M
5.51%
-4.05M
-30.77%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
8.63M
5.23%
+180.41K
+2.13%
Dec 31, 2025
Wellington Management Company, LLP
6.26M
3.79%
-328.49K
-4.99%
Dec 31, 2025
Two Sigma Investments, LP
5.72M
3.46%
+2.07M
+56.76%
Dec 31, 2025
Bellevue Asset Management AG
4.80M
2.91%
-1.44M
-23.10%
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
더 보기
Invesco Biotechnology & Genome ETF
비율5.24%
ARK Genomic Revolution ETF
비율4.11%
Virtus LifeSci Biotech Products ETF
비율3.34%
Franklin Genomic Advancements ETF
비율2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
비율2.57%
First Trust Health Care Alphadex Fund
비율2.47%
VanEck Morningstar SMID Moat ETF
비율2.38%
WisdomTree BioRevolution Fund
비율2.28%
State Street SPDR S&P Biotech ETF
비율2.28%
Capital Group US Small and Mid Cap ETF
비율2.04%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
